Key takeaways
Semglee (insulin glargine-yfgn) and Ozempic (semaglutide) are both medications used to manage Type 2 diabetes, but they belong to different medication classes. Semglee is a long-acting insulin that helps control blood sugar levels by mimicking the natural hormone insulin, while Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist that works by increasing insulin release, reducing sugar production in the liver, and slowing digestion. Semglee is injected once daily, whereas Ozempic is injected once a week. Semglee is available as a vial or prefilled pen, while Ozempic comes as a prefilled pen only. Common side effects of Semglee include headaches, upper respiratory infections, and swelling at the injection site, while Ozempic may cause nausea, vomiting, and diarrhea. Both medications can lead to low blood sugar, especially when taken with other diabetes medications, but Ozempic also carries a risk of thyroid cancer and pancreatitis. Semglee is a biosimilar to Lantus and it can be substituted for Lantus without needing approval from your prescriber, while Ozempic is not interchangeable with other semaglutide products like Wegovy or Rybelsus.
